Kamada (KMDA)
NASDAQ:KMDA
Want to see KMDA full AI Analyst Report?
Earnings Data
Report Date
May 26, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.12Last Year’s EPS
0.07Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call was predominantly positive: Kamada reported double-digit revenue growth (+12%), strong adjusted EBITDA expansion (+23%), a 40% increase in net income, solid operating cash generation, a declared dividend, and constructive 2026 organic guidance (+13% revenue midpoint). Commercial strengths include strong KEDRAB performance with multi-year commitments, GLASSIA contribution, VARIZIG growth and secured Canadian tender, plus planned biosimilar launches and plasma collection expansion that provide multi-year upside. Offsetting items include a decline in CYTOGAM revenues due to increased antiviral use, a modest gross margin decline (42% vs 43%), a small reduction in cash balance after dividend and financing uses, higher G&A, Q4 sequential margin pressure, and a multi-year timeline to realize specialty plasma margin benefits. Overall, the positive operational and financial momentum and confident organic guidance materially outweigh the headwinds.Company Guidance
Revenue Growth
Total revenues of $180.5M in 2025, up 12% year-over-year from $161M in 2024.
Adjusted EBITDA Expansion
Adjusted EBITDA of $42.0M in 2025, a 23% increase versus $34.1M in 2024.
Net Income and EPS Improvement
Net income of $20.2M, or $0.35 per diluted share, a 40% increase from $14.5M ($0.25 per diluted share) in 2024.
Strong Operating Cash Generation and Cash Position
Generated $25.5M of cash from operating activities in 2025, ending the year with $75.5M in cash and cash equivalents.
Shareholder Return — Dividend Declared
Board declared a $0.25 per share dividend totaling approximately $14.4M, reinforcing confidence in liquidity and business prospects.
2026 Organic Guidance Driving Double-Digit Growth
2026 guidance: revenues $200M–$205M and adjusted EBITDA $50M–$53M. Midpoint implies ~13% revenue growth and ~23% adjusted EBITDA growth versus 2025, based solely on organic growth.
KEDRAB Commercial Strength and Multi-Year Commitment
KEDRAB sales to Kedrion ~ $54M in 2025 (well above contract minimum). Kedrion committed to $90M minimum orders for 2026–2027; supply agreement runs through 2031.
GLASSIA and VARIZIG Contributions
GLASSIA contributed ~$35M in 2025 via ex-U.S. product sales and royalties. VARIZIG saw significant sales growth in 2025 driven by decreased vaccination rates, field marketing, and a WHO tender for Latin America.
Distribution Expansion and Biosimilars Ramp
Two additional biosimilars planned for launch in Israel around mid-2026; company expects biosimilars annual sales of $15M–$20M within 4–5 years and has started distribution expansion into the MENA region.
Plasma Collection Build-Out and Future Revenue Streams
Houston center FDA approved; San Antonio expected FDA approval in H1 2026. Each new center has ~50 donor beds and ~50,000 L/year peak capacity; expected normal-source plasma revenues of $8M–$10M per center at full capacity. Current ramp at ~30%–40%; full ramp expected by end of 2027. Specialty plasma expected to positively impact gross profit starting 2027.
Canadian Tender Extension Secured
December award: $10M–$14M extension from Canadian blood services for supply of WINRHO, HEPAGAM, CYTOGAM, and VARIZIG for an additional two years (Q2 2026–Q1 2028), securing near-term revenue visibility.
KMDA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
KMDA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 11, 2026 | $8.70 | $8.30 | -4.58% |
Nov 10, 2025 | $6.46 | $6.81 | +5.40% |
Aug 13, 2025 | $7.26 | $7.16 | -1.34% |
May 14, 2025 | $6.69 | $6.84 | +2.32% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Kamada (KMDA) report earnings?
Kamada (KMDA) is schdueled to report earning on May 26, 2026, Before Open (Confirmed).
What is Kamada (KMDA) earnings time?
Kamada (KMDA) earnings time is at May 26, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KMDA EPS forecast?
KMDA EPS forecast for the fiscal quarter 2026 (Q1) is 0.12.